Botulinum toxin, also called “miracle poison”, is one of the most poisonous biological substances. It is a neurotoxin produced by the bacterium Clostridium botulinum, a Gram-positive anaerobic spore-forming bacillus commonly found in plants, soil, water and the intestinal tract of animals. Botulinum toxin induces striated muscle weakness by inhibiting alpha motor neuron transmission at the neuromuscular junction. This has led to its use in conditions of muscle overactivity, such as dystonia. Transmission is also inhibited in muscle spindle gamma neurons, which may impair reflex overactivity. The toxin also inhibits the release of acetylcholine from all cholinergic and parasympathetic postganglionic sympathetic neurons. This has prompted interest in its use as a treatment for overactive smooth muscle (eg, in achalasia) or abnormal gland activity (eg, hyperhidrosis).

The global Botulinum Toxin Market was estimated at USD 5.8 billion in 2021 and is expected to reach USD 13.1 billion by 2031, registering a CAGR of 8.6% from 2022 to 2031. The report provides a detailed analysis of key investment pockets, key winning strategies, drivers and opportunities, market size and estimations, competitive landscape, and evolving market trends. Market research is a useful source of information for early adopters, new entrants, investors and shareholders as they strategize for the future and increase their market position.

Download Free Sample Report:
Covid-19 scenario-

  • The outbreak of the pandemic gave way to cancellation of several non-essential procedures, which impacted the global botulinum toxin market negatively.
  • However, the market has now got back on track.

The global Botulinum Toxin market is analyzed on the basis of application, product, end user, and region. The report performs a comprehensive analysis of segments and their sub-segments with the help of tabular and graphical representation. Investors and market players can take advantage of the breakdown and devise stratagems based on the fastest growing and highest revenue generating segments noted in the report.

By application, the therapeutic segment accounted for more than half of the global botulinum toxin market revenue in 2021 and is expected to dominate by 2031. The cosmetics segment, on the other hand, would show the fastest CAGR of 9.3% over the entire forecast period.

Speak to our Analyst :

 By product, the Botulinum Toxin Type A segment captured over 90% of the global Botulinum Toxin market share in 2021 and is projected to dominate by 2031. The Botulinum Toxin Type B segment would, concurrently, project the CAGR faster than 9.9% over the entire forecast period. By end-user, the Dermatology & Specialty Clinics segment held more than half of the global Botulinum Toxin market revenue in 2021 and is expected to dominate by 2031. The same segment would also cite the fastest CAGR of 9.3% across the entire forecast period. Depending on the region, the North American market generated nearly two-fifths of the global botulinum toxin market share in 2021 and is projected to retain the majority by 2031. However, the Asia-Pacific region would report the fastest CAGR of 9, 8% during the forecast period. The other provinces analyzed through the relationship include Lamea and Europe.

The key market players analyzed in the global botulinum toxin market report include Merz Pharma GmbH And Co. Kgaa , Us Worldmed, Llc, Abbvie Inc (Allergan), Ipsen Group , Revance Therapeutics Inc, Daewoong Pharmaceutical, Medy-Tox, Inc., Hugel, Inc., Galderma, and Evolus Inc.

These market players have embraced several strategies including partnership, expansion, collaboration, joint ventures, and others to highlight their prowess in the industry. The report is helpful in formulating the business performance and developments by the top players. 

Leave a comment

Your email address will not be published. Required fields are marked *